Drug intelligence / Profile preview

MelCancerVac

Development stage
Phase 2
Lead developer
Lunai Bioworks
Modality
Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration
Intradermal (based On Standard Practice For Dendritic Cell Vaccines; Specific Route Not Explicitly Stated In Sources But Inferred From Clinical Context)
01

Overview

MelCancerVac is a dendritic cell-based therapeutic cancer vaccine developed for the treatment of various solid tumors, including metastatic colorectal cancer, breast cancer, advanced colorectal adenocarcinoma, and melanoma. The vaccine utilizes autologous dendritic cells loaded with tumor antigens to stimulate the patient's immune system toward a Th1-dominated response against tumor cells. Clinical studies have shown that the vaccine is non-toxic and safe, with some patients achieving stable disease and maintaining high quality of life during treatment. Immunological analyses indicate increased levels of Th1 cytokines (such as GM-CSF, TNF-alpha, IFN-gamma, IL-2) in patients who respond to therapy[1][2].

Brand names
MelCancerVac
Other names
MelCancerVac

Beyond the preview

Go deeper on MelCancerVac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MelCancerVac.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call